In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amneal Pharmaceuticals, Inc.

http://www.amneal.com

Latest From Amneal Pharmaceuticals, Inc.

FTC’s Salvos Against Biopharma To Reverberate Through 2024

The Federal Trade Commission broke new ground last year in its opposition to M&A transactions and challenge of Orange Book patent listings. The biopharma community is waiting to see if deals will face similar hurdles in 2024 and whether there will be legal battles if manufacturers of drug-device combination products decline to delist their patents. Researchers advocate that the FTC extend its inquiry to device patents on GLP-1 receptor agonists, including Wegovy and Ozempic.

M & A Patents

No 'Constraining Situation' On Generic Vascepa API, Says Strides MD

Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business.

Strategy Ingredients

No “Constraining Situation” On gVascepa API Says Strides MD, Q3 Revenues Jump

Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business

Commercial Sales & Earnings

Amneal Insists Generics Are Sustainable As It Eyes Further Growth Avenues

Amneal trumpeted its continued faith in the retail generics market at the recent J.P. Morgan Healthcare Conference, as the US-based player also discussed longer-term goals for its burgeoning injectables and biosimilars portfolios.

Biosimilars Generic Drugs
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Amedra Pharmaceuticals LLC
    • Amneal Pharmaceuticals, LLC
    • CorePharma LLC
    • Gemini Laboratories, LLC
    • Impax Generics
    • Impax Laboratories, Inc. (IPXL)
    • Impax Specialty Pharma
    • Lineage Therapeutics Inc.
    • Tower Holdings, Inc.
UsernamePublicRestriction

Register